Bayer's new prostate cancer drug Xofigo's listing application is officially accepted by CDE

recently, Bayer
's application for the listing of the new drug(http://Xofigo (223Ra) was officially accepted by CDEXofigoXofigo was first approved by theFDA(http://on May 15, 2013 to treat advanced bone metastatic resistance to prostate cancerIn phase 3 ALSYMPCA study, Xofigo combined best support therapy (BSoC) compared to the placebo combined BSoC group, which increased total survival by 3.6 months (14.9 vs 11.3 months) and reduced the risk of death by 30 percentIn addition, patients treated with Xofigo were delayed after the first symptomatic bone event (15.6 vs 9.8 months) compared to a placeboIn 2017, Xofigo's global sales reached 408 million eurosXofigo Global SalesRadiotherapydrug(http://has become a big hit in 2018 Following Xofigo, the FDA in January approved The of Advanced Accelerator Applications (http:// 177 Lu-oxodotretide for the treatment of gastrointestinal pancreatic neuroendocrine tumors that were acquired by Novartis in early October for $3.9 billion and then novican, which entered the field of radiotherapy drugs, went on to acquire Endocyte on October 18 for $2.1 billion, acquiring its phase III first-in-class program 177Lu-PSMA-617 for the treatment of metastatic resistance to prostate cancer, and continued to strengthen the radioactive drug pipeline